Table 1. Clinical characteristics of 154 EOC patients.
| Characteristics | Stage | Patients (n) | Median | Percentage/range |
|---|---|---|---|---|
| Age | <50 years | 56 | 58 years | 36.4% |
| ≥50 years | 98 | 58 years | 63.6% | |
| Histology | Serous | 96 | 62.3% | |
| Endometrioid | 35 | 22.72% | ||
| Mucinous | 9 | 5.84% | ||
| Clear cell | 5 | 3.2% | ||
| Mixed type | 9 | 5.84% | ||
| FIGO stage | I–II | 34 | 22.1% | |
| III–IV | 120 | 77.9% | ||
| Grade | 1 | 39 | 25.3% | |
| 2 | 68 | 44.2% | ||
| 3 | 47 | 30.5% | ||
| Tumor residual size | 0 | 41 | 26.6% | |
| <1 cm | 76 | 49.4% | ||
| >1 cm | 37 | 24.0% | ||
| Platinum-based | Cisplatin | 41 | 26.6% | |
| Carboplatin | 113 | 73.4% | ||
| Follow-up time | 154 | 37.2 months | 2–60 months |
EOC, epithelial ovarian cancer.